Landlocked developing countries (LLDCs) vs Laos: Percentage of bloodstream infection due … methicillin-resistant
Landlocked developing countries (LLDCs)
53.8%
in 2022
Laos
55.9%
in 2022
Landlocked developing countries (LLDCs) rank
4th
Laos rank
6th
Percentage of bloodstream infection due … methicillin-resistant over time
- Landlocked developing countries (LLDCs)
- Laos
How they compare
Laos currently reports 55.9% against 53.8% in Landlocked developing countries (LLDCs), a difference of 2.1%.
The two have swapped places 4 times across 6 shared years of data; in 2017 it was Laos ahead.
Landlocked developing countries (LLDCs) ranks 4th and Laos ranks 6th of 15 groups.
Landlocked developing countries (LLDCs) has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Landlocked developing countries (LLDCs) | Laos | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 17.2% | 9.0% | 8.2% | Landlocked developing countries (LLDCs) |
| 2020s | 62.2% | 45.3% | 17.0% | Landlocked developing countries (LLDCs) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to methicillin-resistant, Landlocked developing countries (LLDCs) or Laos?
- Laos, at 55.9% against 53.8% in Landlocked developing countries (LLDCs) as of 2022.
- What is the difference in percentage of bloodstream infection due to methicillin-resistant between Landlocked developing countries (LLDCs) and Laos?
- 2.1%, with Laos ahead.
- How many years of comparable data are there for Landlocked developing countries (LLDCs) and Laos?
- 6 years are reported by both, from 2017 to 2022.
- How do Landlocked developing countries (LLDCs) and Laos rank globally for percentage of bloodstream infection due to methicillin-resistant?
- Landlocked developing countries (LLDCs) ranks 4th and Laos ranks 6th of 15 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.